PharmaCyte Biotech (OTCMKTS:PMCBD) Trading Up 0.1% – Here’s Why

PharmaCyte Biotech Inc (OTCMKTS:PMCBD)’s stock price was up 0.1% during mid-day trading on Tuesday . The company traded as high as $0.74 and last traded at $0.7286. Approximately 54,865 shares changed hands during mid-day trading, an increase of 521% from the average daily volume of 8,831 shares. The stock had previously closed at $0.7277.

PharmaCyte Biotech Stock Performance

The firm’s 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.81.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.

In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.